PDE2A
protein-codingphosphodiesterase 2A, the group of Phosphodiesterases|MicroRNA protein coding host genes
Gene summary
Enables several functions, including 3',5'-cyclic-nucleotide phosphodiesterase activity; anion binding activity; and metal ion binding activity. Involved in several processes, including cGMP catabolic process; cellular response to cytokine stimulus; and regulation of vascular permeability. Located in several cellular components, including cytosol; mitochondrial membrane; and perinuclear region of cytoplasm. [provided by Alliance of Genome Resources, Jun 2026]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~98.5 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0030900
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0030900
Submitter: Labcorp Genetics (formerly Invitae)
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Neurologic
Intervention: Neurologic
Rationale: While the seizures have been desribed as refractory to antieepileptic mediactions, medical management (eg, with vigabatrin) has been reported as transiently improving the neurologic abnormalities in an individual, and deep brain neurostimulation has been described as resulting in clinical improvement of the movement disorder
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to PDE2A variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_002599.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 3 | 94 | 2 | 99 | ||
| missense | 2 | 1 | 133 | 4 | 1 | 141 |
| nonsense | 1 | 2 | 3 | |||
| start loss | 0 | |||||
| frameshift | 1 | 1 | ||||
| splice donor/acceptor (+/-2bp) | 1 | 2 | 7 | 10 | ||
| Total | 5 | 3 | 145 | 98 | 3 | 254 |
Highest pathogenic variant AF is 0.0000022068268
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_002590.1 | 31 | MANE Select | |
| Ensembl | ENSP00000334910.5 | 31 | MANE Select | |
| RefSeq | NP_001137311.1 | 30 | Standard | |
| RefSeq | NP_001139681.1 | 31 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Aldosterone synthesis and secretion - Homo sapiens (human)
- Purine metabolism - Homo sapiens (human)
- cGMP-PKG signaling pathway - Homo sapiens (human)
- Olfactory transduction - Homo sapiens (human)
- Morphine addiction - Homo sapiens (human)
Biological Process
- negative regulation of transcription by RNA polymerase II
- G protein-coupled receptor signaling pathway
- adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway
- positive regulation of gene expression
- negative regulation of cGMP-mediated signaling
Molecular Function
- magnesium ion binding
- 3',5'-cyclic-AMP phosphodiesterase activity
- cGMP-stimulated cyclic-nucleotide phosphodiesterase activity
- calcium channel activity
- protein binding
Cellular Component
- nucleus
- cytoplasm
- mitochondrial outer membrane
- mitochondrial inner membrane
- mitochondrial matrix
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000334456
- Coding exons
- 31
- Length
- 98451
- Individuals with no LoFs
- 125729
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 19
- Defined
- 125748
- p
- 0.0000756
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 4.06 | 271 | 535 | 0.507 | 0.0000284 | 6172 |
| Missense (PolyPhen) | 43 | 177.48 | 0.24229 | 1917 | ||
| Synonymous | 0.381 | 214 | 221 | 0.967 | 0.0000126 | 1750 |
| Loss of Function | 5.44 | 12 | 55.9 | 0.215 | 0.00000266 | 635 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0.000029 | 0.000029 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00022 | 0.00022 | rare |
| Finnish | 0.000046 | 0.000046 | rare |
| European (Non-Finnish) | 0.000099 | 0.000079 | rare |
| South Asian | 0.00013 | 0.00013 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Cyclic nucleotide phosphodiesterase with a dual- specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Plays an important role in growth and invasion of malignant melanoma cells (e.g. pseudomyxoma peritonei (PMP) cell line) (PubMed:24705027). {ECO:0000269|PubMed:24705027}.;
Recessive Scores
- pRec
- 0.183
Intolerance Scores
- LoFtool
- 0.400
- RVIS EVS
- -1.09
- RVIS percentile EVS
- 7.15
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.664
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |